What may seem like a technical exercise in global health bureaucracy- the World Health Organization’s update to its Essential ...

Childhood type 2 diabetes that was rare is now on rise alarmingly in India possibly due to obesity, lifestyle changes and ...

The competition to develop obesity treatments that are more convenient and powerful than Wegovy and Mounjaro is intensifying. Since the popularization ...

European Association for the Study of Diabetes Opens on September 15Simpler and More Potent... The Race to Develop Obesity ...

Discover investment opportunities in Rezolute, Inc. as new drug ersodetug advances in phase 3 HI trials, with catalysts ...

I'm very happy to be here with the CEO of Rezolute, Nevan Elam. This is Kelly McCarthy from the Morgan Stanley Healthcare team and really excited to have you at our conference. I know you got a great ...

The global Medical Sensors Market, valued at US$2.82 billion in 2024, stood at US$3.06 billion in 2025 and is projected to advance at a resilient ...

ENDO 2025 featured the latest research on novel therapies for adrenal and neuroendocrine conditions, new data on various ...

How a venomous lizard, the Gila Monster's saliva, led to one of the biggest scientific discoveries to reduce food appetite in ...

Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.8% ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Frontiers in Endocrinology is a contributor to the 2025 Top 10 Emerging Technologies Report launched at the WEF Annual ...